A randomized controlled 1-year study of daily deferiprone plus twice weekly desferoxamine compared with daily deferiprone monotherapy in patients with thalassemia major

71Citations
Citations of this article
41Readers
Mendeley users who have this article in their library.

Abstract

Background and Objectives: The aim of this prospective, randomized, 1-year study was to compare the efficacy and safety of oral deferiprone (DFP) with those of combinations of parenteral desferrioxamine (DFO) with oral DFP. Design and Methods: A total of 24 patients with thalassemia major were randomized to receive one of the following two treatments; DFP given at a daily dose of 75 mg/kg in combination with DFO (40-50 mg/kg twice weekly) (n=12) or as single agent (n=12). In addition, 12 patients treated with 40-50 mg/kg DFO 5 days weekly were included as a reference group without randomization. Changes in liver iron concentration (LIC) and serum ferritin (SF) were assessed; total iron excretion (TIE), urinary iron excretion (UIE) and iron balance were calculated. Cardiac function and toxicity were also examined. Design and Methods: SF and LIC were significantly reduced after 1 year of combination therapy (p=0.01 and 0.07, respectively). A decrease of LIC was observed in all but one patient (87.5%) following the combination therapy but in only 42% of patients treated with DFP monotherapy. In the DFO reference group, a statistically significant decrease in LIC (p=0.01) associated with a substantial decrease in SF (p=0.08) was observed after 1 year. The combination regimen resulted in greater TIE compared to DFP monotherapy (p=0.08) and was the regimen associated with the highest iron balance compared to DFP monotherapy (p=0.04) or standard DFO treatment (p=0.006). Interpretations and Conclusions: The addition of subcutaneous DFO twice weekly to oral DFP 75 mg/kg is a highly efficacious and safe chelation therapy providing superior chelation activity to that of DFP and likely has an efficacy profile comparable to that of standard DFO. ©2007 Ferrata Storti Foundation.

References Powered by Scopus

Histological grading and staging of chronic hepatitis

4537Citations
N/AReaders
Get full text

Iron-chelating therapy and the treatment of thalassemia

965Citations
N/AReaders
Get full text

Hepatic iron concentration and total body iron stores in thalassemia major

549Citations
N/AReaders
Get full text

Cited by Powered by Scopus

388Citations
N/AReaders
Get full text

Iron overload in thalassemia: Different organs at different rates

212Citations
N/AReaders
Get full text

An update on iron chelation therapy

196Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Aydinok, Y., Ulger, Z., Nart, D., Terzi, A., Cetiner, N., Ellis, G., … Manz, C. (2007). A randomized controlled 1-year study of daily deferiprone plus twice weekly desferoxamine compared with daily deferiprone monotherapy in patients with thalassemia major. Haematologica, 92(12), 1599–1606. https://doi.org/10.3324/haematol.11414

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 15

60%

Researcher 6

24%

Professor / Associate Prof. 2

8%

Lecturer / Post doc 2

8%

Readers' Discipline

Tooltip

Medicine and Dentistry 16

73%

Pharmacology, Toxicology and Pharmaceut... 3

14%

Chemistry 2

9%

Decision Sciences 1

5%

Save time finding and organizing research with Mendeley

Sign up for free